

Research Evidence Sheet

SEO recommendation topic: **Topic 1 - Depression**

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial

Raison CL, Sanacora G, Woolley J, et al. JAMA. 2023;330(9):843-853.

Developing controlled evidence

ACCESS STATUS: The complete journal article is not reproduced in this Satya business binder. No unrestricted redistribution license was verified for commercial reuse. This binder provides an access sheet and official link rather than reproducing the article.

Study design	Phase 2 randomized, placebo-controlled, six-week trial of a single 25 mg psilocybin dose vs niacin with psychological support.
Population	104 adults with major depressive disorder at 11 U.S. research sites.
Why it matters to this SEO topic	A larger multicenter MDD trial than many earlier studies and therefore important to the overall depression evidence base.

What the study found

- Psilocybin was associated with significantly greater reductions in MADRS depression scores than niacin through day 43.
- Disability scores also improved more in the psilocybin group.
- No serious treatment-emergent adverse events were reported in the trial.

Important limitations / boundaries

- Phase 2 trial; replication and longer-term evidence remain important.
- Psychedelic effects can compromise blinding even with an active placebo.
- The research protocol included psychological support and strict screening.

How this can be used responsibly in Satya content

- Supports saying that a multicenter randomized MDD trial found greater symptom reduction with psilocybin than active placebo.
- Avoid claiming the trial proves routine real-world effectiveness or that Satya delivers the same protocol.

Important: Clinical-trial results are evidence about the study population and protocol. They do not establish that Oregon psilocybin services at Satya will reproduce the same outcomes, and they should not be presented as a guarantee of benefit.

Official source / access

[Open the official study page](#)

DOI: [10.1001/jama.2023.14530](https://doi.org/10.1001/jama.2023.14530)

Binder rights note: No unrestricted redistribution license was verified for commercial reuse. This binder provides an access sheet and official link rather than reproducing the article.

Evidence library reviewed: August 7, 2026